Hussain M, et al. PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. ESMO Congress 2019, abstract LBA12_PR.
Landelijke campagne bevolkingsonderzoek baarmoederhalskanker van start
jan 2024 | Gynaecologische oncologie, Virale infecties